Outlook Therapeutics details LYTENAVA US launch prep in Q3 FY2026 update

Outlook Therapeutics gave a business update on LYTENAVA (bevacizumab-vikg, bevacizumab gamma) alongside its third quarter fiscal 2026 results for the period ended June 30, 2026.

CEO Bob Jahr said the company's priorities include building an exceptional commercial team with deep retina and launch experience, preparing for a planned U.S. launch by the end of calendar 2026, and executing a strategy that reflects the competitive and evolving wet AMD treatment landscape.¹ The company said it is expanding payer engagement, scaling commercial supply, and building a focused commercial organization informed by feedback from retina physicians, practices, and other key stakeholders.¹

As part of reimbursement preparation, the company plans to submit an application for a permanent Healthcare Common Procedure Coding System, or HCPCS, code by October 1, 2026, to support reimbursement following launch.¹ Management said based on current estimates, LYTENAVA has the potential to exceed $500 million in annual U.S. sales by 2030.¹

In Europe, the company continues to expand commercialization in Germany, Austria and the United Kingdom, is preparing for a planned launch in the Netherlands later in 2026, and its partner Mediconsult is leading regulatory and commercial activities for an anticipated 2027 launch in Switzerland.¹

On finances, the company reported a net loss attributable to common stockholders of $20.3 million, or $0.15 per share, for the quarter, compared with $20.2 million, or $0.55 per share, a year earlier.¹ As of quarter end, Outlook Therapeutics had cash and cash equivalents of $11.2 million, which does not include the proceeds from the public offering.¹ After the quarter closed, the company announced a public offering of 55,555,556 shares of common stock and accompanying warrants at a combined price of $0.99 per share and warrant, for approximately $51.1 million in net proceeds after fees.¹